1400583-12-1

Basic information

• Product Name: Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester
• Synonyms: Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester;METHYL 3-((TERT-BUTOXYCARBONYL)AMINO)CYCLOPENTANE-1-CARBOXYLATE
• CAS NO: 1400583-12-1
• Molecular Formula: C12H21NO4
• Molecular Weight: 243.29944
• Mol File: 1400583-12-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester(1400583-12-1)
• EPA Substance Registry System: Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester(1400583-12-1)

Safety Data

• Hazardous Substances Data: 1400583-12-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester is used as a key intermediate in the synthesis of drug molecules for various therapeutic applications. Its unique structure and reactivity allow for the development of new medications with improved efficacy and safety profiles.
Used in Drug Synthesis:
Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester is utilized as a starting material or a building block in the synthesis of complex drug molecules. Its presence of an amino group and a diMethylethoxy carbonyl group enables the formation of diverse chemical linkages and interactions, contributing to the creation of innovative pharmaceutical agents.
It is crucial to handle and use Cyclopentanecarboxylic acid, 3-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester with care, adhering to proper safety protocols to minimize any potential adverse effects on human health and the environment.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 147698-10-0 (S)-3--(methoxycarbonyl)cyclopentene 
• 789468-94-6 methyl (1R,3S)-3-aminocyclopentane-1-carboxylate 
• 1085842-51-8 methyl (1S,3S)-3-aminocyclopentane-1-carboxylate hydrochloride 
• 67-56-1 methanol 
• 489446-85-7 (1R,3R)-3-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylic acid 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 200002-41-1 (-)-[(1R,4S)-tert-butyl 3-oxo-2-azabicyclo(2.2.1)hept-5-ene-2-carboxylate] 
• 693245-53-3 tert-butyl (1R,4S)-3-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 124-41-4 sodium methylate 
• 261165-05-3 (1S,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 167081-32-5 3-oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester 

Downstream Products

• 167081-31-4 ((1S,3S)-3-hydroxymethylcyclopentyl)carbamic acid tert-butyl ester 
• 489446-72-2 (1R,3R)-3-tert-butoxycarbonylaminocyclopentanecarboxylic acid methyl ester 
• 180323-49-3 (1S,3R)-methyl 3-aminocyclopentanecarboxylate hydrochloride 

Relevant articles and documents

Highly selective directed hydrogenation of enantiopure 4-(tert-butoxycarbonylamino)cyclopent-1-enecarboxylic acid methyl esters

The use of both N-tert-butoxycarbonylamino- and hydroxyl-directed hydrogenation methodology to yield essentially single diastereomers of 3-(tert-butoxycarbonylamino)-4-hydroxycyclopentanecarboxylic acid methyl esters and 3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid methyl esters is described. These results incorporate the first reported carbamate-directed hydrogenations of functionalised cyclopentenes.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

PYRAZOLO-PYRIMIDIN-AMINO-CYCLOALKYL COMPOUNDS AND THEIR THERAPEUTIC USES

Disclosed herein are pyrazolo-pyrimid in-ami no-cycloalkyl compounds, analogs thereof, pharmaceutical compositions comprising thereof and therapeutic uses therefor.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

COMPLEMENT PATHWAY MODULATORS AND USES THEREOF

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

NICOTINAMIDE DERIVATIVES

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the trea

NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION

The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, -COOR3, CONR3R4, -OR3, -NR3R4, or NR3COR3; R2 is hydrogen, cyano, COOH, or an isostere of a carboxylic acid (such as SO3H, CONOH, B(OH)2, PO3R3R4, SO2NR3R4, tetrazole, -COOR3, -CONR3R4, NR3COR4, or -COOCOR3).

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclero